Pfizer Company Profile (NYSE:PFE)

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:PFE
  • CUSIP: 71708110
  • Web:
  • Market Cap: $213.92616 billion
  • Outstanding Shares: 5,947,349,000
Average Prices:
  • 50 Day Moving Avg: $33.78
  • 200 Day Moving Avg: $33.53
  • 52 Week Range: $29.83 - $36.12
  • Trailing P/E Ratio: 26.20
  • Foreward P/E Ratio: 13.12
  • P/E Growth: 2.48
Sales & Book Value:
  • Annual Revenue: $52.35 billion
  • Price / Sales: 4.09
  • Book Value: $9.81 per share
  • Price / Book: 3.67
  • Annual Dividend: $1.28
  • Dividend Yield: 3.6%
  • EBIDTA: $20.24 billion
  • Net Margins: 15.84%
  • Return on Equity: 24.51%
  • Return on Assets: 8.60%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 1.34%
  • Quick Ratio: 1.06%
  • Average Volume: 17.37 million shs.
  • Beta: 1
  • Short Ratio: 2.37

Frequently Asked Questions for Pfizer (NYSE:PFE)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, June 22nd. Shareholders of record on Friday, August 4th will be given a dividend of $0.32 per share on Friday, September 1st. This represents a $1.28 annualized dividend and a yield of 3.56%. The ex-dividend date of this dividend is Wednesday, August 2nd. View Pfizer's Dividend History.

How were Pfizer's earnings last quarter?

Pfizer, Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, August, 1st. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.64 EPS. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of $2.54-2.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.55. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $52.78 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

18 equities research analysts have issued 12-month price targets for Pfizer's stock. Their forecasts range from $31.00 to $53.00. On average, they expect Pfizer's stock price to reach $38.31 in the next twelve months. View Analyst Ratings for Pfizer.

What are analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. According to Zacks Investment Research, "Pfizer has been working on strengthening its product portfolio as well as key pipeline milestones through acquisitions and licensing deals. New products like Ibrance and contribution from acquisitions are expected to drive revenues. Also, cost-savings and share buybacks should help Pfizer achieve its earnings guidance. Investor focus will remain on the stock as Pfizer has several key pipeline milestones in 2017. However, genericization of key drugs, lost alliance revenues, pricing pressure and rising competition remain potent headwinds. Mounting competition in the immuno-oncology market is also a significant concern. Meanwhile, Pfizer’s shares have underperformed the large-cap pharma industry this year so far. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q2 earnings release. " (7/14/2017)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 3. UBS AG analysts commented, " The FDA approved Novartis' CDK4/6 agent, Kisqali (ribociclib), in first-line treatment for HR+/HER2- metastatic breast cancer in combo with any aromatase inhibitor. Recall that MONALEESA-2 was stopped early, and while interim data demonstrated a reduction in risk of disease progression or death by 44% over letrozole alone, the mPFS had not been reached at the time. For the first time, the label presented a mPFS of 25.3 mos for Kisqali + letrozole vs 16 mos for letrozole alone. The 9.3 mos improvement over letrozole is essentially comparable to 10.3 mos improvement (24.8 mos for Ibrance vs 14.5 mos for letrozole) for Pfizer's Ibrance. Given the strong interim data that were comparable to Ibrance, we believe the approval of Kisqali was largely expected. Our takeaway: Label looks a little worse than Ibrance. Overall, we think the label looks slightly worse, particularly on safety. On the positive, the label is broader, as the indication is for use of Kisqali in combo with anyaromatase inhibitors (vs Ibrance in combo with letrozole). However, as the vast majority of first-line use letrozole, the broader label shouldn't meaningfully impact Ibrance, in our view. We're not clear on how Kisqali got the broader label, but we think this could be encouraging for Ibrance, as the Ibrance label could also become as broad with the potential April approval of the confirmatory Phase 3 PALOMA-2 (Ibrance was approved under an accelerated pathway with Phase 2 PALOMA-1 data). On safety, the Kisqali label warns of QT prolongation and liver tox, which are not in the Ibrance label. We think the QT issue could put Kisqali at a disadvantage. Thoughts on the stock: Shouldn't impact the stock much, if anyIbrance has been on the market for ~2 years and has made significant headway to becoming a standard of therapy, and we do not believe there was anything in the Kisqali label that would meaningfully impact the significant lead that Pfizer has. In our CDK4/6 model, we assign a 5% share for Kisqali in 2017 that goes to 15%, 18%, and 20% in 2018-2020E." (3/14/2017)
  • 4. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in August. As of August 31st, there was short interest totalling 45,068,122 shares, an increase of 11.5% from the August 15th total of 40,434,475 shares. Based on an average daily volume of 14,631,410 shares, the short-interest ratio is currently 3.1 days. Approximately 0.8% of the shares of the company are sold short.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations
  • Albert Bourla, Group President - Pfizer Innovative Health
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development
  • John D. Young, Group President - Pfizer Essential Health
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer
  • Douglas M. Lankler, Executive Vice President, General Counsel
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer
  • Kirsten Lund-Jurgensen, Executive Vice President, President - Pfizer Global Supply

Who owns Pfizer stock?

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (26.39%), Vanguard Group Inc. (25.03%), State Street Corp (5.30%), Northern Trust Corp (4.65%), Bank of New York Mellon Corp (3.85%) and State Farm Mutual Automobile Insurance Co. (3.57%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Cibc World Markets Corp, Lazard Asset Management LLC, Maverick Capital Ltd., Bank of New York Mellon Corp, BlackRock Inc., FIL Ltd, Schroder Investment Management Group and State Street Corp. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Frank A Damelio, Ian C Read, Laurie J Olson, Mikael Dolsten, Rady A Johnson and Sally Susman. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vanguard Group Inc., Renaissance Technologies LLC, Canada Pension Plan Investment Board, Parametric Portfolio Associates LLC, Principal Financial Group Inc., Marshall Wace North America L.P. and Sentry Investments Corp.. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $35.96.

MarketBeat Community Rating for Pfizer (NYSE PFE)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  832 (Vote Outperform)
Underperform Votes:  423 (Vote Underperform)
Total Votes:  1,255
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pfizer (NYSE:PFE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $38.31 (6.54% upside)

Analysts' Ratings History for Pfizer (NYSE:PFE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Morgan StanleyUpgradeEqual Weight -> Overweight$35.00 -> $39.00LowView Rating Details
9/19/2017Sanford C. BernsteinSet Price TargetBuy$39.00LowView Rating Details
9/18/2017Jefferies Group LLCSet Price TargetNeutral$37.00LowView Rating Details
9/14/2017BMO Capital MarketsReiterated RatingBuy$37.00HighView Rating Details
8/15/2017Berenberg BankReiterated RatingHold$39.00 -> $36.00LowView Rating Details
8/14/2017Cowen and CompanySet Price TargetBuy$43.00LowView Rating Details
7/20/2017Credit Suisse GroupDowngradeOutperform -> Neutral$38.00 -> $36.00LowView Rating Details
5/16/2017Citigroup Inc.DowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
5/3/2017Barclays PLCReiterated RatingBuy$38.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
2/16/2017Deutsche Bank AGReiterated RatingBuy$40.00N/AView Rating Details
2/2/2017Morningstar, Inc.Reiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$36.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of America CorporationReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
8/3/2016J P Morgan Chase & CoSet Price TargetBuy$40.00N/AView Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust Banks, Inc.Lower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
1/26/2016Nord/LBReiterated RatingBuyN/AView Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for Pfizer (NYSE:PFE)
Earnings by Quarter for Pfizer (NYSE:PFE)
Earnings History by Quarter for Pfizer (NYSE PFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.64N/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.08 billion$12.90 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfizer (NYSE:PFE)
2017 EPS Consensus Estimate: $2.51
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.67$0.67$0.67
Q2 20173$0.62$0.65$0.64
Q3 20172$0.60$0.61$0.61
Q4 20172$0.59$0.60$0.60
(Data provided by Zacks Investment Research)


Current Dividend Information for Pfizer (NYSE:PFE)
Most Recent Dividend:9/1/2017
Annual Dividend:$1.28
Dividend Yield:3.56%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:94.12% (Trailing 12 Months of Earnings)
50.00% (Based on This Year's Estimates)
46.72% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Dividend History by Quarter for Pfizer (NYSE PFE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pfizer (NYSE:PFE)
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.00%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.80View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.00View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.00View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.70View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pfizer (NYSE:PFE)
Latest Headlines for Pfizer (NYSE:PFE)
DateHeadline logo[$$] Pfizer's Underappreciated Global Opportunity - September 22 at 12:33 PM logoNational Sickle Cell Disease Poll of African Americans Dispels Long-Held Views - September 22 at 12:33 PM logoVersartis growth hormone drug fails key study, shares sink - September 22 at 12:33 PM logoThese Pfizer’s Products Are Now Losing Market Share - September 22 at 12:33 PM logoVersartis' Somavaratan Still Has A Path Forward; Cantor Reiterates Buy - September 22 at 9:49 AM logo$13.17 Billion in Sales Expected for Pfizer, Inc. (PFE) This Quarter - September 21 at 7:48 AM logoPfizer, Inc. (PFE) Rating Increased to Overweight at Morgan Stanley - September 21 at 12:38 AM logoPfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts - September 20 at 7:38 AM logoPfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery - September 20 at 7:38 AM logoAd Com vote split on Pfizer's Sutent for certain kidney cancer patients - September 19 at 1:56 PM logoPfizer, Inc. (PFE) Given a $39.00 Price Target by Sanford C. Bernstein Analysts - September 19 at 11:57 AM logoInteresting October Stock Options for PFE - Nasdaq - September 19 at 6:27 AM logoPfizer, Inc. (PFE) Given a $37.00 Price Target at Jefferies Group LLC - September 18 at 9:40 AM logoPfizer, Inc. (PFE) Short Interest Update - September 18 at 2:48 AM logoPfizer, Inc. (PFE) Stock Rating Lowered by Vetr Inc. - September 17 at 4:32 PM logoBetter Buy: Pfizer Inc. vs. Bristol-Myers Squibb - September 17 at 7:52 AM logoSunTrust Banks Comments on Pfizer, Inc.'s Q4 2017 Earnings (PFE) - September 15 at 9:28 AM logoRecent Buy: Pfizer Inc. - September 15 at 7:30 AM logoPfizer Announces Positive Late Stage Trial of Cancer Treatment - September 15 at 7:30 AM logoHow This Dow Component Could Double Its Prostate-Cancer Market - September 15 at 7:30 AM logoPharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO - September 15 at 7:30 AM logoMarkets Right Now: Dow ekes out another high in mixed day - September 14 at 4:31 PM logoPfizer, Inc. (PFE) Insider Sells $1,338,050.00 in Stock - September 14 at 10:25 AM logoPfizer, Inc. (PFE) Rating Reiterated by BMO Capital Markets - September 14 at 9:51 AM logoPfizer, Astellas Report Positive Results From XTANDI Phase 3 Trial - Quick Facts - September 14 at 9:09 AM logoIs There Now An Opportunity In Pfizer Inc (PFE)? - September 14 at 9:09 AM logoPfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer - September 14 at 9:09 AM logoPfizer, Astellas prostate cancer drug succeeds key trial - September 14 at 9:09 AM logoUS STOCKS-Futures flat ahead of key inflation data - September 14 at 9:09 AM logoPfizer shares rise 1.4% after news of positive late-stage cancer trial - September 14 at 9:09 AM logoBrokers Set Expectations for Pfizer, Inc.'s FY2017 Earnings (PFE) - September 14 at 7:42 AM logoPfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer - September 12 at 8:34 AM logoAllergan's Patent Loophole Could Be a Huge Gift for Pfizer - September 12 at 8:34 AM logoAllergan's Patent Loophole Could Be a Huge Gift for Pfizer - September 11 at 7:29 AM logoPfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress - September 10 at 6:23 AM logoPfizer’s Meridian Hit With FDA Warning Over EpiPen Flaws - September 9 at 7:16 AM logo[$$] Pfizer CEO, CFO Sell $13 Million in Stock - September 9 at 7:16 AM logoPfizer Accused of Not Investigating EpiPen Failures - September 8 at 11:49 AM logoFDA Accuses EpiPen Maker of Failing to Investigate Malfunctions - New York Times - September 8 at 10:39 AM logoPfizer Inc. (PFE) Given Average Rating of "Hold" by Analysts - September 7 at 2:46 AM logoPfizer Inc. (PFE) Given Buy Rating at BMO Capital Markets - September 6 at 1:28 PM logoAlexander R. Mackenzie Sells 7,350 Shares of Pfizer, Inc. (PFE) Stock - September 5 at 8:06 PM logoPfizer's Acute Leukemia Drug Mylotarg Approved by the FDA - September 4 at 9:42 PM logoPfizer Inc (PFE) Chairman & CEO Ian C Read Sold $6.7 million of Shares - September 4 at 5:28 AM logoPfizer’s Sterile Injection Pharmaceuticals in 2Q17 and 1H17 - September 2 at 7:27 AM logoHow Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17 - September 2 at 7:27 AM logoPfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin) - September 2 at 7:26 AM logoPfizer Inc. : PFE-US: Dividend Analysis : August 04th, 2017 (record date) : By the numbers : September 1, 2017 - September 2 at 7:26 AM logoPfizer, Inc. (PFE) Expected to Announce Quarterly Sales of $13.16 Billion - September 2 at 1:40 AM logoPfizer, Inc. (PFE) EVP Sells $3,209,906.00 in Stock - September 1 at 7:22 PM



Pfizer (PFE) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff